[Ross R. Atherosclerosis - an inflammatory disease. N Engl J Med. 1999; 340(2): 115-126.10.1056/NEJM1999011434002079887164]Search in Google Scholar
[Pickup JC, Crook MA. Is type II diabetes mellitus a disease of the innate immune system? Diabetologia. 1998; 41(10): 1241-1248.10.1007/s0012500510589794114]Search in Google Scholar
[Libby P. Inflammation in atherosclerosis. Nature. 2002; 420(6917):868-874.10.1038/nature0132312490960]Search in Google Scholar
[Haffner SM. Coronary heart disease in patients with diabetes. N Engl J Med. 2000; 342(14): 1040-1042.10.1056/NEJM20000406342140810749967]Search in Google Scholar
[Gerdes N, Sukhova GK, Libby P, Reynolds RS, Young JL, Schonbeck U. Expression of interleukin (IL)-18 and functional IL-18 receptor on human vascular endothelial cells, smooth muscle cells, and macrophages: implications for atherogenesis. J Exp Med. 2002; 195(2): 245-257.10.1084/jem.20011022219360711805151]Search in Google Scholar
[Mallat Z, Corbaz A, Scoazec A, Besnard S, Leseche G, Chvatchko Y, Tedgui A. Expression of interleukin-18 in human atherosclerotic plaques and relation to plaque instability. Circulation. 2001; 104(104): 1598-1603.10.1161/hc3901.09672111581135]Search in Google Scholar
[Whitman SC, Ravisankar P, Daugherty A. Interleukin-18 enhances atherosclerosis in apolipoprotein E(-/-) mice through release of interferon-γ. Circ Res. 2002; 90(2): e34-e38.10.1161/hh0202.10529211834721]Search in Google Scholar
[Mallat Z, Corbaz A, Scoazec A, Graber P, Alouani S, Esposito B, Humbert Y, Chvatchko Y, Tedgui A. Interleukin-18/interleukin-18 binding protein signaling modulates atherosclerotic lesion development and stability. Circ Res. 2001; 89(7): e41-e45.10.1161/hh1901.09873511577031]Search in Google Scholar
[Mallat Z, Henry P, Fressonnet R, Alouani S, Scoazec A, Beaufils P, Chvatchko Y, Tedgui A. Increased plasma concentrations of interleukin-18 in acute coronary syndromes. Heart. 2002; 88(5): 467-469.10.1136/heart.88.5.467176743112381634]Search in Google Scholar
[Esposito K, Nappo F, Giugliano D, Di Palo C, Ciotola M, Barbieri M, Paolisso G, Giugliano D. Cyokine milieu tends toward inflammation in type 2 diabetes. Diabetes Care. 2003; 26(5): 1647.10.2337/diacare.26.5.164712716849]Search in Google Scholar
[Aso Y, Okumura KI, Takebayashi K, Wakabayashi S, Inukai T. Relationships of plasma interleukin-18 concentrations to hyperhomocysteinemia and carotid intima-media wall thickness in patients with type 2 diabetes. Diabetes Care. 2003; 26(9): 2622-2627.10.2337/diacare.26.9.2622]Search in Google Scholar
[Esposito K, Nappo F, Marfella R, Giugliano G, Giugliano F, Ciotola M, Quagliaro L, Ceriello A, Giugliano D. Inflammatory cytokine concentrations are acutely increased by hyperglycemia in humans: role of oxidative stress. Circulation. 2002; 106:(16): 2067-2072.10.1161/01.CIR.0000034509.14906.AE]Search in Google Scholar
[Giedraitis V, He B, Huang WX, Hillert J. Cloning and mutation analysis of the human IL-18 promoter: a possible role of polymorphisms in expression regulation. J Neuroimmunol. 2001; 112(1-2): 146-152.10.1016/S0165-5728(00)00407-0]Search in Google Scholar
[Tiret L, Godefroy T, Lubos E, Nicaud V, Tregouet DA, Barbaux S, Schnabel R, Bickel C, Espinola-Klein C, Poirier O, Perret C, Munzel T, Rupprecht HJ, Lackner K, Cambien F, Blankenberg S, for the AtheroGene Investigators. Genetic analysis of the interleukin-18 aystem highlights the role of the interleukin-18 gene in cardiovascular disease. Circulation. 2005; 112(5): 643-650.10.1161/CIRCULATIONAHA.104.519702]Search in Google Scholar
[Hernesniemi JA, Karhunen PJ, Rontu R, Ilveskoski E, Kajander O, Goebeler S, Viiri LE, Pessi T, Hurme M, Lehtimäki T. Interleukin-18 promoter polymorphism associates with the occurrence of sudden cardiac death among Caucasian males: The Helsinki Sudden Death Study. Atherosclerosis. 2008; 196(2): 643-649.10.1016/j.atherosclerosis.2007.07.018]Search in Google Scholar
[Liu W, Tang Q, Jiang H, Ding X, Liu Y, Zhu R, Tang Y, Li B, Wei M. Promoter polymorphism of inerleukin-18 in angiographically proven coronary artery disease. Angiology. 2009; 60(2): 180-185.10.1177/0003319708319939]Search in Google Scholar
[Kretowski A, Mironczuk K, Karpinska A, Bojaryn U, Kinalski M, Puchalski Z, Kinalska I. Interleukin-18 promoter polymorphisms in type 1 diabetes. Diabetes. 2002; 51(11): 3347-3349.10.2337/diabetes.51.11.3347]Search in Google Scholar
[Bossu P, Ciaramella A, Moro ML, Bellincampi L, Bernardini S, Federici G, Trequattrini A, Macciardi F, Spoletini I, Di Iulio F, Caltagirone C, Spalletta G. Interleukin 18 gene polymorphisms predict risk and outcome of Alzheimer's disease. J Neurol Neurosurg Psychiatry 2007; 78(8): 807-811.10.1136/jnnp.2006.103242]Search in Google Scholar
[Expert Committee on the Diagnosis and Classification of Diabetes Mellitus. Report of the expert committee on the diagnosis and classification of diabetes mellitus. Diabetes Care. 2003; 26(Suppl 1): S5-S20.10.2337/diacare.26.2007.S5]Search in Google Scholar
[Alpert JS, Thygesen K, Antman E, Bassand JP. Myocardial infarction redefined-a consensus document of The Joint European Society of Cardiology/American College of Cardiology Committee for the redefinition of myocardial infarction. J Am Coll Cardiol. 2000; 36(3): 959-969.10.1016/S0735-1097(00)00804-4]Search in Google Scholar
[Szeszko JS, Howson JM, Cooper JD, Walker NM, Twells RC, Stevens HE, Nutland SL, Todd JA. Analysis of polymorphisms of the interleukin-18 gene in type 1 diabetes and Hardy-Weinberg equilibrium testing. Diabetes. 2006; 55(2): 559-562.10.2337/diabetes.55.02.06.db05-082616443795]Search in Google Scholar
[Ford E. Body mass index, diabetes, and C-reactive protein among U.S. adults. Diabetes Care. 1999; 22(12): 1971-1977.]Search in Google Scholar
[Schulze M, Rifai N, Rimm E, Stampfer M, Li T, Hu F. C-reactive protein and incident cardiovascular events among men with diabetes. Diabetes Care. 2004; 27(4): 889-894.10.2337/diacare.27.4.88915047644]Search in Google Scholar
[Soinio M, Marniemi J, Laakso M, Lehto S, Rönnemaa T. High-sensitivity C-reactive protein and coronary heart disease mortality in patients with type 2 diabetes: a 7-year follow-up study. Diabetes Care. 2006; 29(2): 329-333.10.2337/diacare.29.02.06.dc05-170016443882]Search in Google Scholar
[Nakamura A, Shikata K, Hiramatsu M, Nakatou T, Kitamura T, Wada J, Itoshima T, Makino H. Serum interleukin-18 levels are associated with nephropathy and atherosclerosis in Japanese patients with type 2 diabetes. Diabetes Care. 2005; 28(12): 2890-2895.10.2337/diacare.28.12.289016306550]Search in Google Scholar
[Troseid M, Seljeflot I, Hjerkinn EM, Arnesen H. Interleukin-18 is a strong predictor of cardiovascular events in elderly men with the metabolic syndrome: synergistic effect of inflammation and hyperglycemia. Diabetes Care. 2009; 32(3): 486-492.10.2337/dc08-1710264603419092166]Search in Google Scholar
[Thorand B, Kolb H, Baumert J, Koenig W, Chambless L, Meisinger C, Illig T, Martin S, Herder C. Elevated levels of interleukin-18 predict the development of type 2 diabetes: results from the MONICA/KORA Augsburg Study, 1984-2002. Diabetes. 2005; 54(10): 2932-2938.10.2337/diabetes.54.10.293216186395]Search in Google Scholar
[Tenger C, Sundborger A, Jawien J, Zhou X. IL-18 accelerates atherosclerosis accompanied by elevation of IFN-gamma and CXCL16 expression independently of T cells. Arterioscler Thromb Vasc Biol. 2005; 25(4): 791-796.10.1161/01.ATV.0000153516.02782.6515604417]Search in Google Scholar
[Rosso R, Roth A, Herz I, Miller H, Keren G, George J. Serum levels of interleukin-18 in patients with stable and unstable angina pectoris. Int J Cardiol. 2005; 98(1): 45-48.10.1016/j.ijcard.2003.08.02015676165]Search in Google Scholar
[Hulthe J, McPheat W, Samnegard A, Tornvall P, Hamsten A, Eriksson P. Plasma interleukin (IL)-18 concentrations is elevated in patients with previous myocardial infarction and related to severity of coronary atherosclerosis independently of C-reactive protein and IL-6. Atherosclerosis. 2006; 188(2): 450-454.10.1016/j.atherosclerosis.2005.11.01316405895]Search in Google Scholar
[Blankenberg S, Tiret L, Bickel C, Peetz D, Cambien F, Meyer J, Rupprecht Interleukin 18 is a strong predictor of cardiovascular death in stable and unstable angina. Circulation. 2002; HJ. 106(1): 24-30.10.1161/01.CIR.0000020546.30940.9212093765]Search in Google Scholar
[Blankenberg S, Luc G, Ducimetière P, Arveiler D, Ferrières J, Amouyel P, Evans A, Cambien F, Tiret L, on behalf of the PRIME Study Group. Interleukin-18 and the risk of coronary heart disease in European men: The Prospective Epidemiological Study of Myocardial Infarction (PRIME). Circulation. 2003; 108(20): 2453-2459.10.1161/01.CIR.0000099509.76044.A214581397]Search in Google Scholar
[Arimitsu J, Hirano T, Higa S, Kawai M, Naka T, Ogata A, Shima Y, Fujimoto M, Yamadori T, Hagiwara K, Ohgawara T, Kuwabara Y, Kawase I, Tanaka T. IL-18 gene polymorphisms affect IL-18 production capability by monocytes. Biochem Biophys Res Commun. 2006; 342(4): 1413-1416.10.1016/j.bbrc.2006.02.09616516851]Search in Google Scholar
[Hernesniemi JA, Karhunen PJ, Oksala N, Kähönen M, Levula M, Rontu R, Ilveskoski E, Kajander O, Goebeler S, Viiri LE, Hurme M, Lehtimäki T. Interleukin 18 gene promoter polymorphism: a link between hypertension and pre-hospital sudden cardiac death: the Helsinki Sudden Death Study. Eur Heart J. 2009; 30(23): 2939-2946.10.1093/eurheartj/ehp31619687159]Search in Google Scholar
[Kathiresan S, Newton-Cheh C, Gerszten RE. On the interpretation of genetic association studies. Eur Heart J. 2004; 25(16): 1378-1381.10.1016/j.ehj.2004.06.03515321696]Search in Google Scholar